Skip to main content

Table 2 Comorbidities in the UHH cohort

From: Pirfenidone improves survival in IPF: results from a real-life study

Comorbidities N = 82
Systemic Hypertension 58 (64%)
Gastroesophageal Reflux Disease 42 (47%)
Ischemic Heart Disease 27 (30%)
Heart Failure 25 (28%)
Diabetes Mellitus 24 (27%)
Obstructive Sleep Apnea-Hypopnea Syndrome 23 (26%)
Depression 21 (23%)
Emphysema 19 (21%)
Pulmonary Hypertension 12 (13%)
Lung Cancer 2 (2%)
Venous Thromboembolism 1 (1%)